The North American Menopause Society Issues Position Statement on Hormone Therapy

Share this content:

(ChemotherapyAdvisor) – The North American Menopause Society (NAMS) has published a 2012 position statement that provides updated evidence for use of hormone therapy for postmenopausal women. Further distinguished since the 2010 statement was published are emerging differences in the therapeutic benefit-risk ratio between estrogen therapy and combined estrogen-progestogen therapy at various ages and time intervals since menopause onset.

For example, “the more favorable benefit-risk ratio for estrogen therapy allows more flexibility in extending the duration of use compared with combined estrogen-progestogen therapy, where the earlier appearance of increased breast-cancer risk precludes a recommendation for use beyond three to five years,” the statement notes.

The position statement reviews effects of hormone therapy on many aspects of women's health and includes a discussion of endometrial, lung, and ovarian cancer.

North American Menopause Society Position Statement

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs